BioMarin investing $43M in fill-finish line at plant in Ireland

BioMarin
BioMarin's plant in Ireland is the first outside the U.S. for the genetic disease specialist. (BioMarin)

BioMarin had its first manufacturing site outside of the U.S. approved just last year. But the genetic disease specialist is already expanding the site in Ireland and adding dozens of new jobs.

The drugmaker will invest about $43 million in a filling line at the bulk biologics plant in Shanbally, County Cork, and is expected to bring on 51 employees as a result, according to an announcement from the Ireland Development Agency.

The new filling line will supplement its drug substance manufacturing and secondary packaging and labeling capabilities. It already has about 350 workers at the facility.

Survey

Survey: The Critical Role of Innovation in Launching Successful OTC Products

This research aims to understand the importance of product innovation and dose forms in driving new product design and development, consumer engagement and purchase interest for Over-the-Counter medicines. The first 50 qualified respondents will receive a $5 Amazon gift card. Take the survey now.

“The introduction of fill finish capacity at Shanbally provides for fully integrated manufacturing from bulk to drug product onsite,” BioMarin Executive VP Robert Baffi, Ph.D., said in a statement. “This expansion assures that an increasing amount of our commercial products will be manufactured at the site.”

RELATED: FDA gives nod to BioMarin’s Ireland bulk biologic manufacturing facility 

BioMarin bought the operation from Pfizer in 2011 to diversify its manufacturing risk. The site has already been expanded to include an expanded warehouse, utilities and new office space. Last year, it moved manufacturing of Vimizim, its drug for Morquio A syndrome, an enzyme deficiency that interferes with skeletal development and can trigger a host of other health problems.

Suggested Articles

Perrigo is treading water in its specialty drugs reinvention plan. Could a merger with another struggling drugmaker—à la Pfizer and Mylan—be the cure?

Companies routinely update analysts, but a new SEC order for tiny TherapeuticsMD offers a lesson—or reminder—about when to keep quiet.

AveXis' ex-CSO is "prepared to assert his rights and defend his conduct accordingly," a statement from a lawyer who recently represented Elon…